Login
Immunogen NASDAQ: IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.
| Name | Immunogen |
| Ticker | IMGN |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 3.68 |
| 52W Low/High | 2.12 / 6.80 |
| Market cap | 642 M |
| 1Y Total Return |
32.37%
Strong |
| 1Y Volatility |
97.79%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.
Details
| Ticker | IMGN |
| Name | Immunogen |
| ISIN | US45253H1014 |
| CUSIP | 45253H101 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 9/25/20
| Close Price | 3.68 |
| 52W Low/High | 2.12 / 6.80 |
| Market cap | 642 M |
| 1Y Total Return |
32.37%
Strong |
| 1Y Volatility |
97.79%
High Risk |
| Beta | 0.96 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -81.3% |
| Cash from Op. / Cur. Liabilities | -1.37 |
| Diluted Earnings / Share | -0.42 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 7.4 |
| Price / Book | -26.2 |
| Price / CF | -5.2 |
| Current Ratio | 2.7 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
86
|
48
|
77
|
89
|
60
|
86
|
|
| Gross Profit |
86
|
48
|
77
|
89
|
60
|
86
|
|
| R&D |
97
|
158
|
155
|
135
|
148
|
112
|
|
| EBITDA |
-68
|
-171
|
-141
|
-95
|
-139
|
-55
|
|
| Operating Income |
-52
|
-169
|
-116
|
-86
|
-125
|
-54
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
174
|
148
|
134
|
87
|
87
|
86
|
|
| EPS exc. Extra |
-0.42
|
-1.20
|
-1.27
|
-1.21
|
-1.67
|
-0.71
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
270
|
288
|
381
|
181
|
279
|
314
|
|
| Cash, Eq & Invt ShortTerm |
220
|
240
|
345
|
150
|
245
|
278
|
|
| Total Current Assets |
241
|
259
|
365
|
161
|
253
|
292
|
|
| Total Non-Current Assets |
28
|
28
|
16
|
20
|
26
|
22
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
294
|
356
|
292
|
355
|
362
|
279
|
|
| Total Current Liabilities |
91
|
75
|
63
|
67
|
60
|
36
|
|
| Long Term Debt |
203
|
281
|
229
|
287
|
301
|
243
|
|
| Shareholder equity |
-25
|
-68
|
89
|
-173
|
-82
|
35
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-124
|
-102
|
-69
|
-93
|
-124
|
-55
|
|
| Depreciation |
3
|
5
|
8
|
6
|
5
|
6
|
|
| Cash from Investing |
3
|
-5
|
-2
|
-2
|
-10
|
-7
|
|
| Capex |
3
|
5
|
2
|
2
|
10
|
7
|
|
| Cash from Financing |
101
|
2
|
266
|
0
|
102
|
199
|
|
| Stock Issued |
101
|
2
|
268
|
0
|
5
|
4
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
97
|
0
|
|
| Free Cash Flow |
-64
|
-163
|
-149
|
-99
|
-113
|
-56
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
2.7
|
3.5
|
5.8
|
2.4
|
4.2
|
8.2
|
|
| Financial Leverage D/E |
-
|
-
|
0.02
|
-
|
-
|
0.00
|
|
| Return on Capital Avg |
-
|
-
|
-
|
-
|
-
|
-7,116.5%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available